| Today’s Big NewsFeb 28, 2024 |
| By Max Bayer With the stage set for the first psychedelic-based therapy to nab FDA approval this year, even J.P. Morgan can't resist the allure of compelling data and wide-open markets. |
|
|
|
By Gabrielle Masson After being the center of speculation for several months, Cytokinetics’ CEO Robert Blum is putting the kibosh on the rumor that Novartis will be acquiring the biotech. |
By James Waldron With its money and options dwindling, ObsEva has finally decided to wind down operations and lay off all its employees. |
Sponsored by The Dedham Group The influence of oncology pathways is growing. Here are the challenges and opportunities for biopharma companies in the clinical pathways landscape. |
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Sign Up Today! +(1)+(1).png)
|
|
By Nick Paul Taylor Idorsia has survived a high-wire financing act. Weeks from the end of its cash runway, the biotech has secured $350 million upfront from Viatris in exchange for the global rights to two phase 3 candidates. |
Sponsored by Sengenics Revolutionizing Cancer Detection: The Power of Autoantibodies |
By Nick Paul Taylor AbbVie is talkin’ bout a resolution. The Big Pharma has bet $48 million on OSE Immunotherapeutics’ antibody platform, handing the biotech the upfront fee and dangling another $665 million in milestones for global rights to a novel approach to chronic inflammation. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
By Annalee Armstrong Palatin Technologies has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal of improving a clinical sign of the disorder. |
By James Waldron Layoffs are in store for employees at both Longeveron and Nicox, although neither company is spelling out how many staff will be affected. |
By Helen Floersh Mouse data from a new study sponsored in part by Chroma Medicine suggests that epigenetic gene silencing can suppress the target gene for nearly a year, providing new evidence for the lasting effects of epigenetic therapies. |
By Conor Hale The spending spree comes alongside Ginkgo’s unveiling of a new technology network that encompasses a list of offerings from more than 25 of the company’s developer partners and previous acquisitions. |
By Fraiser Kansteiner As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024. |
By Andrea Park The FDA put out a safety communication Tuesday warning about the possibility of “serious complications” tied to the use of Hologic’s BioZorb devices. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Editor-in-Chief Ayla Ellison explores the critical issue of maternal mental health in an interview with Dr. Ken Levey, co-founder and CEO of Mother Goose Health. |
|
|---|
|
|
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
